| Highly Selective Dopamine D3 Receptor (D3R) Antagonists and Partial Agonists Based on Eticlopride and the D3R Crystal Structure: New Leads for Opioid … V Kumar, A Bonifazi, MP Ellenberger, TM Keck, E Pommier, R Rais, ... Journal of medicinal chemistry 59 (16), 7634-7650, 2016 | 93 | 2016 |
| Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-like receptor agonist M Sánchez-Soto, A Bonifazi, NS Cai, MP Ellenberger, AH Newman, ... Molecular pharmacology 89 (4), 457-466, 2016 | 74 | 2016 |
| The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents CJ Jordan, B Humburg, M Rice, GH Bi, ZB You, AB Shaik, J Cao, ... Neuropharmacology 158, 107597, 2019 | 67 | 2019 |
| Novel and high affinity 2-[(diphenylmethyl) sulfinyl] acetamide (modafinil) analogues as atypical dopamine transporter inhibitors J Cao, RD Slack, OM Bakare, C Burzynski, R Rais, BS Slusher, T Kopajtic, ... Journal of medicinal chemistry 59 (23), 10676-10691, 2016 | 65 | 2016 |
| Pharmacological profiling of sigma 1 receptor ligands by novel receptor homomer assays H Yano, A Bonifazi, M Xu, DA Guthrie, SN Schneck, AM Abramyan, ... Neuropharmacology 133, 264-275, 2018 | 63 | 2018 |
| 2016 Philip S. Portoghese medicinal chemistry lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts AH Newman, FO Battiti, A Bonifazi Journal of medicinal chemistry 63 (5), 1779-1797, 2019 | 55 | 2019 |
| Toward Understanding the Structural Basis of Partial Agonism at the Dopamine D3 Receptor M Michino, CA Boateng, P Donthamsetti, H Yano, OM Bakare, A Bonifazi, ... Journal of medicinal chemistry 60 (2), 580-593, 2017 | 54 | 2017 |
| Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation MB Morelli, C Amantini, M Nabissi, S Liberati, C Cardinali, V Farfariello, ... BMC cancer 14, 1-13, 2014 | 51 | 2014 |
| Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids NS Cai, C Quiroz, J Bonaventura, A Bonifazi, TO Cole, J Purks, AS Billing, ... The Journal of clinical investigation 129 (7), 2730-2744, 2019 | 50 | 2019 |
| New drugs, old targets: tweaking the dopamine system to treat psychostimulant use disorders AH Newman, T Ku, CJ Jordan, A Bonifazi, ZX Xi Annual review of pharmacology and toxicology 61 (1), 609-628, 2021 | 49 | 2021 |
| Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists A Bonifazi, H Yano, AM Guerrero, V Kumar, AF Hoffman, CR Lupica, L Shi, ... ACS pharmacology & translational science 2 (1), 52-65, 2019 | 49 | 2019 |
| Synthesis and pharmacological characterization of novel trans-cyclopropylmethyl-linked bivalent ligands that exhibit selectivity and allosteric pharmacology at the dopamine D3 … V Kumar, AE Moritz, TM Keck, A Bonifazi, MP Ellenberger, CD Sibley, ... Journal of medicinal chemistry 60 (4), 1478-1494, 2017 | 49 | 2017 |
| Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism A Bonifazi, H Yano, MP Ellenberger, L Muller, V Kumar, MF Zou, NS Cai, ... Journal of medicinal chemistry 60 (7), 2890-2907, 2017 | 43 | 2017 |
| Favourable involvement of α2A-adrenoreceptor antagonism in the I2-imidazoline binding sites-mediated morphine analgesia enhancement V Mammoli, A Bonifazi, F Del Bello, E Diamanti, M Giannella, AL Hudson, ... Bioorganic & medicinal chemistry 20 (7), 2259-2265, 2012 | 43 | 2012 |
| Novel Analogues of (R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Sumanirole) Provide Clues to Dopamine D2/D3 Receptor … MF Zou, TM Keck, V Kumar, P Donthamsetti, M Michino, C Burzynski, ... Journal of medicinal chemistry 59 (7), 2973-2988, 2016 | 38 | 2016 |
| Using click chemistry toward novel 1, 2, 3-triazole-linked dopamine D3 receptor ligands TM Keck, AK Banala, RD Slack, C Burzynski, A Bonifazi, ... Bioorganic & medicinal chemistry 23 (14), 4000-4012, 2015 | 35 | 2015 |
| Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl) propyl]-1, 2, 3, 4 … A Bonifazi, H Yano, F Del Bello, A Farande, W Quaglia, R Petrelli, ... Journal of medicinal chemistry 57 (21), 9065-9077, 2014 | 35 | 2014 |
| Investigation of novel primary and secondary pharmacophores and 3-substitution in the linking chain of a series of highly selective and bitopic dopamine D3 receptor antagonists … AB Shaik, V Kumar, A Bonifazi, AM Guerrero, SL Cemaj, A Gadiano, ... Journal of medicinal chemistry 62 (20), 9061-9077, 2019 | 34 | 2019 |
| The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D3 Receptor (D3R) Selective Agonists FO Battiti, SL Cemaj, AM Guerrero, AB Shaik, J Lam, R Rais, BS Slusher, ... Journal of medicinal chemistry 62 (13), 6287-6314, 2019 | 31 | 2019 |
| Dopamine D4 Receptor-Selective Compounds Reveal Structure–Activity Relationships that Engender Agonist Efficacy TM Keck, RB Free, MM Day, SL Brown, MS Maddaluna, G Fountain, ... Journal of medicinal chemistry 62 (7), 3722-3740, 2019 | 30 | 2019 |
